# Maria De Santis

Source: https://onco.cc/people/maria-de-santis/  
OnCo record `maria-de-santis` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Berlin oncologist who led SEMPET, the study showing that a PET scan can tell which residual masses after chemotherapy for seminoma still contain cancer, sparing many men further treatment.

## Summary

Maria De Santis is a genitourinary medical oncologist at Charité in Berlin. She was first author of the 2004 Journal of Clinical Oncology report of the SEMPET study, which showed that FDG-PET reliably distinguished viable tumour from fibrosis in residual masses after chemotherapy for seminoma, particularly for masses over 3 cm, a finding adopted into guidelines. She is also a leading investigator in urothelial cancer and chairs the EAU testis cancer guideline panel.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: testis; imaging; trialist
- Role: Genitourinary medical oncologist, Charité Universitätsmedizin Berlin
- Specialisms: Germ cell tumours; Bladder cancer; Positron emission tomography in oncology

## Connected records

- cancers: [Seminoma](https://onco.cc/cancers/seminoma/)
- institutions: [Charité Universitätsmedizin Berlin](https://onco.cc/institutions/charite/)
- key papers: [SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals](https://onco.cc/key-papers/paper-sempet-de-santis-jco-2004/)

---
JSON: https://onco.cc/api/v1/entities/maria-de-santis.json